ABL Bio Inc. (KOSDAQ:298380)

South Korea flag South Korea · Delayed Price · Currency is KRW
88,100
+6,500 (7.97%)
Aug 14, 2025, 2:40 PM KST
184.19%
Market Cap 4.45T
Revenue (ttm) 27.63B
Net Income (ttm) -71.71B
Shares Out 54.58M
EPS (ttm) -1,489.50
PE Ratio n/a
Forward PE 136.50
Dividend n/a
Ex-Dividend Date n/a
Volume 3,067,364
Average Volume 1,233,752
Open 83,700
Previous Close 81,600
Day's Range 81,800 - 90,500
52-Week Range 25,950 - 93,900
Beta 0.77
RSI 60.13
Earnings Date Aug 11, 2025

About ABL Bio

ABL Bio Inc., a biotech research company, focuses on the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline drugs include ABL001, cancer immunotherapy, ADC, and ABL301. ABL Bio Inc.is headquartered in Seongnam-si, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
CEO Sang Hoon Lee
Employees 102
Stock Exchange KOSDAQ
Ticker Symbol 298380
Full Company Profile

Financial Performance

In 2024, ABL Bio's revenue was 33.40 billion, a decrease of -49.04% compared to the previous year's 65.55 billion. Losses were -55.53 billion, 1998.1% more than in 2023.

Financial Statements

News

There is no news available yet.